ArticleJournal of multidisciplinary healthcare2025
Metabolism-Mediated FGF5 Association with Stroke: Based on Mendelian Randomization and Bioinformatics Analysis.
Article in Journal of multidisciplinary healthcare, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sex differences in proteomic response to ischemic stroke.Biology of sex differences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Stroke is the second leading cause of death and the third leading cause of disability worldwide. The role of fibroblast growth factor 5 (FGF5) in the occurrence and development of stroke remains unclear. We used bidirectional Mendelian randomization (MR) analysis to evaluate the mediating role of metabolites and causal association between inflammatory factors and stroke. Methods: We analyzed the stroke dataset from the FinnGen database (v11) (cases: 43,132; Control: 297,867). Data on metabolites and inflammatory factors were obtained from the genome-wide Association Studies (GWAS) catalog of the European Institute for Bioinformatics (EBI). Using expression data of FGF5 mRNA and protein in the Comprehensive Gene Expression Database (GEO) and clinical data, expression level and clinical relevance of FGF5 in stroke were explored. The protein-protein interaction (PPI) network of FGF5-related genes was constructed, and various bioinformatics analyses (including functional enrichment, immune infiltration analysis, etc) were conducted to evaluate its functional mechanism. Results: FGF5 was significantly associated with stroke risk (inverse variance weighting method (IVW): odds ratio (OR) = 1.052, 95% confidence interval (CI): 1.021-1.084, P<0.01). Mediation analysis indicated that inflammatory factors influenced stroke risk through the metabolites 1-palmitoyl-phosphoglycerol (GPG) [effect: 0.00462 (-0.0102, 0.001); mediated effect: 9.09% (-20.2%, 1.97%)], 1-stearoyl-2-arachidonoyl-phosphoethanolamine (GPE) [effect: 0.00274 (-0.00212, 0.0076); mediated effect: 5.39% (4.17%, 14.9%). Among them, the mediating effect of 1-palmitoyl phosphatidylglycerol (GPG) was not significant. Furthermore, FGF5 is associated with epithelial cell proliferation, peptidyl-tyrosine phosphorylation, CD4+ primary T cells and M0 macrophages. Conclusion: This study, by integrating multiple omics methods, such as Mendelian randomization, expression profiling analysis, and bioinformatics, has for the first time established FGF5 as a novel potential biomarker for stroke risk. Inflammatory factors can mediate the molecular pathways of stroke occurrence through metabolites such as GPE. The value of FGF5 as a novel biomarker for the diagnosis/prognosis of stroke and the new mechanism of stroke-related metabolic regulatory network provide a theoretical basis for targeted intervention of stroke.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.